Medincell (France) Executives
| MEDCL Stock | EUR 16.50 1.62 8.94% |
Medincell employs about 151 people. The company is managed by 10 executives with a total tenure of roughly 353 years, averaging almost 35.0 years of service per executive, having 15.1 employees per reported executive. Discussion of Medincell's management performance can provide insight into the enterprise performance.
| Joel Richard Insider Member Board |
| Quiterie Beauregard Insider Head Portfolio |
Medincell |
Medincell Management Team Effectiveness
The company has return on total asset (ROA) of (0.3954) % which means that it has lost $0.3954 on every $100 spent on assets. This is way below average. Medincell's management efficiency ratios could be used to measure how well Medincell manages its routine affairs as well as how well it operates its assets and liabilities.Medincell Workforce Comparison
Medincell SA is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 1,850. Medincell holds roughly 151 in number of employees claiming about 8% of stocks in Biotechnology industry.
Medincell SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medincell SA Price Series Summation is a cross summation of Medincell price series and its benchmark/peer.
Medincell Notable Stakeholders
A Medincell stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medincell often face trade-offs trying to please all of them. Medincell's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medincell's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joel Richard | Member Board | Profile | |
| Quiterie Beauregard | Head Portfolio | Profile | |
| Helen Martin | Head Management | Profile | |
| Julie Alimi | Head Legal | Profile | |
| Sebastien Enault | Chief Officer | Profile | |
| Christophe Douat | Chairman of the Management Board | Profile | |
| Jaime Arango | Financial and Administrative Director | Profile | |
| David Heuze | Head Board | Profile | |
| Adolfo Noriega | Head Board | Profile | |
| Franck Pouzache | Chief Officer | Profile |
About Medincell Management Performance
The success or failure of an entity such as Medincell SA often depends on how effective the management is. Medincell management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medincell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medincell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. MEDINCELL is traded on Paris Stock Exchange in France.
Medincell Workforce Analysis
Traditionally, organizations such as Medincell use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medincell within its industry.Medincell Manpower Efficiency
Return on Medincell Manpower
| Revenue Per Employee | 27.1K | |
| Revenue Per Executive | 409K | |
| Net Loss Per Employee | 164.3K | |
| Net Loss Per Executive | 2.5M |
Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.